| Drug Class | Drug |
|---|
| Biological Agents (monoclonal antibodies; Anti-TNF, RA, Chrons) | |
| Osteoporosis Management (Vit D Precursor; converted into Calcidiol (liver), then Calcitriol (kidneys). Acts to ↑Ca2+ by ↑absorption, reabsorption and bone resorption) | |
| Hypercalcaemia Imm. Management | |
| Fluoroquinolone Antibiotic (bacteriostatic, targeting DNA structure/function; Gram -ve infections / MRSA) | |
| Biological Agents (monoclonal antibodies; Anti-CD20 RA, SLE) | |
| Beta-Lactam Antibiotic (Penicillin; bactericidal, targeting cell wall; tonsillitis) | |
| Anti-Proliferative Agents (DMARDs; acts against purine synthesis; RA) | |
| Hypocalcaemia Management (↑ serum Ca2+ to reduce NM symptoms) | |
| Anti-Proliferative Agents (DMARDs; acts against folate activity; RA) | |
| Osteoporosis Management (inhibits RANK-L which prevents osteoclast activation, thus ↓ bone resorption) | |
| Beta-Lactam Antibiotic (Penicillin; bactericidal, targeting cell wall; LRTI) | |
| Tetracycline Antibiotic (bactericidal, targeting RNA & protein synthesis; atypical bacteria that lack cell wall e.g. Chlamydia) | |
| Beta-Lactam Antibiotic (Cephalosporin; bactericidal, targeting cell wall; sepsis/bacterial meningitis - broad spec) | |
| Beta-Lactam Antibiotic (Carbapenem; bactericidal, targeting cell wall; infections in ITU - most broad spec/powerful) | |
| Aminosalicylates (DMARDs; suppress immune-mediated inflammatory response in RA, Mechanism unclear) | |
| SERM (bone-specific oestrogen-R agonist; osteoporosis) | |
| | Drug Class | Drug |
|---|
| Aminosalicylates (DMARDs; suppress immune-mediated inflammatory response in RA, Mechanism unclear) | |
| Beta-Lactam Antibiotic (Penicillin; bactericidal, targeting cell wall; mixed infections) | |
| Loop Diuretic (for hypercalcaemia) | |
| Vitamin D Deficiency (Vit D Precursor; converted into Calcidiol (liver), then Calcitriol (kidneys). Acts to ↑Ca2+ by ↑absorption, reabsorption and bone resorption) | |
| Thyroid Hormone (opposes PTH to ↓ serum Ca2+ by ↓bone resorption & ↓reabsorption; hypercalcaemia) | |
| Vitamin D Deficiency (active form of Vit D; CKD) | |
| Osteoporosis Management (intermittent dose can ↑osteoblast activity and may ↑BMD) | |
| Lincosamide Antibiotic (bacteriostatic, targeting RNA & protein synthesis; SSTI) | |
| Bisphosphonate (disrupt osteoclast function to ↓rate of bone remodelling; first-line for osteoporosis) | |
| Hypocalcaemia Management (Vit D Precursor; converted into Calcidiol (liver), then Calcitriol (kidneys). Acts to ↑Ca2+ by ↑absorption, reabsorption and bone resorption) | |
| Nitroimidazole Antibiotic (bacteriostatic, targeting DNA structure/function; anaerobic infections e.g. abscess) | |
| Tetracycline Antibiotic (bactericidal, targeting RNA & protein synthesis; atypical bacteria that lack cell wall e.g. Chlamydia) | |
| Bisphosphonate (disrupt osteoclast function to ↓rate of bone remodelling; hypercalcaemia) | |
| Macrolide Antibiotic (Bacteriostatic – inhibition of bacterial protein synthesis) | |
| Beta-Lactam Antibiotic (Penicillin; bactericidal, targeting cell wall; SSTI) | |
|
